Weis Holger 4

What Happened Holger Weis, a director of Jupiter Neurosciences, was granted a derivative award on 2026-06-02 covering 100,000 shares. The Form 4 reports the acquisition at $0.00 (derivative/award), indicating an option-style grant rather than a cash purchase or stock sale. The filing does not list an exercise (strike) price or immediate cash value.

Key Details

• Transaction date: 2026-06-02; filing date: 2026-06-04 (timely filing).
• Reported transaction: Award/Grant (code A) of 100,000 share-equivalents at $0.00 (derivative).
• Shares owned after transaction: Not stated in the provided filing.
• Footnote: Options granted under the Issuer's 2025 Equity Incentive Plan vest over three years beginning September 2, 2026, in equal quarterly installments, subject to continued service through each vesting date.
• No indication of a 10b5-1 plan, tax withholding, cashless exercise, or sale of shares in this filing.

Context This was an equity incentive grant to a director (common for compensation), not an immediate purchase or sale. As a derivative/options award, the grant gives the potential to acquire underlying shares in the future if vesting and exercise conditions are met. Because the strike price and total potential value aren’t disclosed in the provided details, the economic impact depends on those terms and future share price movement.